ArticleCureus2026
Sonographic Grading of Non-alcoholic Fatty Liver Disease and Its Association With Serum Biomarkers, Echocardiography, and Electrocardiogram.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionNon-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome and is increasingly recognized as a systemic disorder associated with cardiovascular morbidity. Sonographic grading of NAFLD may reflect progressive metabolic and cardiovascular involvement; however, evidence evaluating the association between ultrasonographic severity and serum biomarkers, echocardiographic parameters, and electrocardiographic findings remains limited. This study aimed to evaluate the association between sonographic grading of NAFLD and serum biomarkers, echocardiographic parameters, and electrocardiographic findings. MATERIALS AND
methodsThis prospective observational study included 96 adults with sonographically diagnosed NAFLD attending a tertiary care center between March 2024 and October 2025. Participants were categorized into Grade 1, Grade 2, and Grade 3 NAFLD based on ultrasonographic findings. Serum lipid profile and liver enzymes were evaluated, followed by transthoracic echocardiography and 12-lead electrocardiography. Continuous variables were compared using one-way analysis of variance with Tukey's post-hoc test, while categorical variables were analyzed using the chi-squared test or Fisher's exact test, as appropriate. A p-value of <0.05 was considered statistically significant.
resultsIncreasing sonographic grade of NAFLD was associated with progressive elevations in total cholesterol, triglyceride, low-density lipoprotein (LDL), very-low-density lipoprotein (VLDL), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) levels, together with a significant reduction in high-density lipoprotein (HDL) levels (all p<0.001). Echocardiographic evaluation demonstrated significant increases in interventricular septal thickness, left ventricular mass, left ventricular mass index, left ventricular dimensions, and progressive reductions in ejection fraction and early-to-late ventricular filling velocity ratio (E/A ratio) (all p<0.001). The prevalence of left ventricular diastolic dysfunction increased from 10 (22.7%) in Grade 1 to 18 (52.9%) in Grade 2 and 14 (77.8%) in Grade 3 (p<0.001). QTc prolongation similarly increased from 6 (13.6%) to 11 (32.4%) and 12 (66.7%) across Grades 1-3 (p<0.001). Although P-wave and T-wave abnormalities were more frequent in advanced disease, these associations were not statistically significant.
conclusionsIncreasing sonographic severity of NAFLD is associated with worsening biochemical abnormalities, adverse cardiac remodelling, left ventricular diastolic dysfunction, and QTc prolongation. Ultrasonographic grading, combined with routine biochemical, echocardiographic, and electrocardiographic evaluation, may facilitate the early cardiovascular risk stratification and comprehensive management of patients with NAFLD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.